Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
We sold Zoetis, as concerns continue to grow about competitive entrants in the dermatology and parasiticides animal health marketplace. While the company...
— Mr. Fitzpatrick
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Zoetis Inc.
Zoetis ($ZTS) is a global leader in animal health, engaged in the discovery, development, and manufacture of veterinary pharmaceuticals, vaccines, and diagnostic products for livestock and companion animals. The manager divested...
Zoetis Inc. ($ZTS) is the global leader in animal health, producing specialized veterinary medicines, vaccines, and diagnostic tests for companion pets and livestock. Middle Coast initiated...
Zoetis Inc. is a dominant player in the animal health industry, but its capital allocation strategy has focused on share buybacks rather than organic growth. The com...
More institutional theses from Aristotle Core Equity Fund
Chart Industries posted positive performance as preliminary 2025 outlooks indicated robust 39% earnings growth despite a Q3 quarterly miss. Management reiterated solid...
The fund established a long position in CrowdStrike to capture secular growth in enterprise cloud migration and security spending. The company's unified...
Aristotle initiated a position in GE Aerospace, citing its dominant position in high-barrier commercial engine manufacturing and long OEM order backlogs. Following significant corporate...